Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2

Article abstract of DOI:10.1021/acs.jmedchem.8b00513

Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias. These mutations cause hyperactivation of SHP2 due to the disruption of the autoinhibitory conformation. By targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor (E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1H-benzo[d]imidazol-2(3H)-one (LY6, 1) using computer-aided drug design database screening combined with cell-based assays. This compound inhibited SHP2 with an IC₅₀ value of 9.8 μM, 7-fold more selective for SHP2 than the highly related SHP1. Fluorescence titration, thermal shift, and microscale thermophoresis quantitative binding assays confirmed its direct binding to SHP2. This compound was further verified to effectively inhibit SHP2-mediated cell signaling and proliferation. Furthermore, mouse and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than wild-type cells. This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further optimization studies to develop novel anti-SHP2 therapeutic agents.

Full text of DOI:10.1021/acs.jmedchem.8b00513

Subscriber access provided by Université de Strasbourg - Service Commun de la Documentation
Article
A small molecule inhibitor that stabilizes the autoinhibited
conformation of the oncogenic tyrosine phosphatase SHP2
Xiaoqin Wu, Gang Xu, Xiaobo Li, Weiren Xu, Qianjin Li, Wei Liu, Karen
A Kirby, Mignon L Loh, Jun Li, Stefan G Sarafianos, and Cheng-Kui Qu
J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.8b00513 • Publication Date (Web): 20 Nov 2018
Downloaded from http://pubs.acs.org on November 20, 2018
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.

Page 1 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
A small molecule inhibitor that stabilizes the autoinhibited conformation of
the oncogenic tyrosine phosphatase SHP2
Xiaoqin Wu1, †, Gang Xu2, †, Xiaobo Li1, 2, †, Weiren Xu2, Qianjin Li1, Wei Liu2, Karen A. Kirby3, Mignon
L. Loh4, Jun Li5, Stefan G. Sarafianos3, and Cheng-Kui Qu1, 2, *
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 Department of Pediatrics, Division of Hematology/Oncology, Aflac Cancer and Blood Disorders Center,
Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA. 2
Department of Medicine, Division of Hematology and Oncology, Case Comprehensive Cancer Center,
Case Western Reserve University, Cleveland, OH 44106, USA. 3 Department of Pediatrics, Laboratory of
4
Biochemical Pharmacology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California, San
Francisco, San Francisco, CA 94122, USA. 5 School of Pharmacy, Anhui Medical University, Hefei,
230032, China.
† These authors contributed equally to this work.
* Correspondence and request for materials should be addressed to:
Cheng-Kui Qu, M.D., Ph.D.
Professor of Pediatrics
Department of Pediatrics
Division of Hematology/Oncology
Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta
Emory University School of Medicine
1760 Haygood Drive NE, HSRB E302
Atlanta, GA 30322
Tel: 404-727-5037
Fax: 404-727-4455
Email: cheng-kui.qu@emory.edu
1
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 2 of 49
1
2
3
4
ABSTRACT
5
6
7
8
9
Genetic mutations in the phosphatase PTPN11 (SHP2) are associated with childhood leukemias. These
mutations cause hyperactivation of SHP2 due to the disruption of the auto-inhibitory conformation. By
targeting the activation-associated protein conformational change, we have identified an SHP2 inhibitor
(E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1H-benzo[d]imidazol-2(3H)-one (LY6, 1) using computer-aided drug design database screening combined
with cell-based assays. This compound inhibited SHP2 with an IC50 value of 9.8 µM, 7-fold more selective
for SHP2 than the highly related SHP1. Fluorescence titration, thermal shift, and microscale
thermophoresis quantitative binding assays confirmed its direct binding to SHP2. This compound was
further verified to effectively inhibit SHP2-mediated cell signaling and proliferation. Furthermore, mouse
and patient leukemia cells with PTPN11 activating mutations were more sensitive to this inhibitor than
wild-type cells. This small molecule SHP2 inhibitor has a potential to serve as a lead compound for further
optimization studies to develop novel anti-SHP2 therapeutic agents.
INTRODUCTION
SHP2 (encoded by PTPN11), a widely expressed non-receptor type protein tyrosine phosphatase (PTP),
plays an essential role in several intracellular signal transduction processes, such as Ras-Erk, PI3K-Akt,
Jak-Stat, NF-B, and mTOR pathways1-3. It contains two Src homology 2 (SH2) domains at the N-terminus
and a PTP domain at the C-terminus. The 2.0 Å X-ray crystal structure of SHP2 reveals that in the basal
state, the catalytic site of SHP2 is autoinhibited by the N-terminal SH2 (N-SH2) domain. The N-SH2
domain of SHP2 functions as a conformational switch, which either binds to the PTP domain and directly
blocks the active site, or binds to phospho-tyrosine (pY)-containing signaling partners and activates the
2
ACS Paragon Plus Environment

Page 3 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
enzyme by disrupting the intra-molecular inhibitory interaction4. The C-SH2 also plays an important role in
recognition of bisphosphorylated ligands and contributes to binding energy and specificity, being an
integral element of the switch5, 6. Although SHP2 dephosphorylates tyrosine phosphorylated signaling
proteins, this phosphatase plays an overall positive role in transduction of the signals initiated from growth
factors, cytokines and extracellular matrix proteins1-3, in sharp contrast to hematopoietic cell-specific SHP1
phosphatase, which shares a similar overall structure and a high homology with SHP2, but plays a negative
role in cell signaling. The molecular mechanism for SHP2 function is not completely understood and is an
area of intensive research. Both the SH2 domains and the PTP domains of SHP2 and SHP1 determine the
signaling and thus functional specificities of these two highly related PTPs.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The critical role of SHP2 in cell signaling and other cellular activities is further underscored by its direct
association with human diseases. Germline or somatic mutations in the PTPN11 gene that cause
hyperactivation of SHP2 catalytic activity have been identified in 50% of patients with the developmental
disorder Noonan Syndrome (NS) and various childhood leukemias, including juvenile myelomonocytic
leukemia (JMML) (~35%), myelodysplastic syndrome (~10%), B cell acute lymphoblastic leukemia
(~7%), and acute myeloid leukemia (~4%)7-11. In addition, activating mutations of PTPN11 have been
found in sporadic solid tumors12. PTPN11 mutations, found in NS, leukemias, and solid tumors disrupt the
intra-molecular interaction of SHP2, leading to a partially open conformation and thus activation of SHP2
due to greatly increased accessibility of the catalytic site11, 13. Several studies have demonstrated that a
single PTPN11 activating mutation is sufficient to induce NS, JMML-like myeloproliferative neoplasm,
and acute leukemias in mice14-16, suggesting that PTPN11 mutations play a causative role in these diseases.
The direct connection between activating mutations of PTPN11 and human diseases makes SHP2 an
3
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 4 of 49
1
2
3
4
5
6
7
8
9
attractive target for developing mechanism-based therapeutic drugs. Identification of SHP2 inhibitors with
high bio-activity will not only be helpful for drug discovery but also for understanding SHP2 function in
cell signaling. However, it is extremely challenging to identify SHP2 selective inhibitors given the high
homology in the catalytic site of SHP2 to those in other tyrosine phosphatases, especially the highly related
SHP1 phosphatase. Over the last decade, several SHP2 inhibitors have been reported17-23. However, their
cross reactivity for other PTPs, off-target effects, or biological functions in PTPN11 mutated tumor cells
have not been well characterized. More recently, a potent and selective inhibitor of SHP2 was identified
through high throughput screening24, 25. This inhibitor concurrently binds to the interface of the N-SH2, C-
SH2, and PTP domains, inhibiting SHP2 activity through an allosteric mechanism. In the present study, we
have chosen to target a different SHP2 surface pocket to identify small molecule compounds that suppress
activation-associated conformational changes to functionally inhibit SHP2. Using computer-aided drug
design (CADD) screening of a virtual database of compounds followed by experimental assays, we have
identified a new low molecular weight compound that inhibits SHP2 activity. It is more than 7-fold
selective for SHP2 over the closest homologue SHP1. Moreover, biological assays have verified that it is
effective in blocking SHP2-mediated signaling and cellular functions in mouse and patient cells.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Results
Determination of a drug binding pocket in SHP2 for CADD database screening. To identify small
molecule inhibitors that are selective for SHP2 over SHP1, we performed thorough sequence and structural
analyses for SHP2 and SHP1. The active site of SHP2 is almost identical to that of the SHP1 phosphatase.
Compounds that target the catalytic core of SHP2 often inhibit SHP1. Therefore, our structure-based
approach was aimed to target the allosteric change required for activation of SHP2, instead of the catalytic
site. SiteMap was used to explore a potential drug-binding site in SHP2 for inhibitor discovery. Five
4
ACS Paragon Plus Environment

Page 5 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
possible binding sites in SHP2 were identified in this study (Figure 1A). The characters of these potential
binding sites were assessed by calculating various properties, such as size, volume, amino acid exposure,
enclosure, contact, hydrophobicity, hydrophilicity, and donor/acceptor ratio. Site 1 had the largest internal
space and it was located at the interface between C-SH2 and PTP domains of SHP2. Site 4 was close to Site
1 and sat at the interface between N-SH2 and PTP domains. Site 3 was also located between N-SH2 and
PTP domains. Both Site 2 and Site 5 were parts of the PTP domain. Site 3 and Site 5 were subsequently
eliminated due to their low scores in the Sitemap algorithm. By analyzing chemical environments and
structural conformations of Site 1 and the other two binding pockets we thought that compounds binding to
Site 1 might tighten the connection of C-SH2 and PTP domains and stabilize the “closed” autoinhibited
conformation of SHP2. More importantly, Site 1 of SHP2 showed specific features, as compared to the
corresponding region of the homology SHP1 (Figure 1B). This pocket in SHP2 may confer biological
selectivity to small molecule compounds that bind to and potentially stabilize the inhibitory conformation
of SHP2. Therefore, Site 1 was selected as the docking site for database screening.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CADD in silico screening and structural optimization. To identify small molecular compounds that bind
to and stabilize the auto-inhibited conformation to functionally inhibit SHP2, virtual chemical structure
database screening and core-hopping procedures were performed. The drug-like structure database of the
National Cancer Institute (NCI), USA, was screened by using Glide of Schrodinger 2010 based on the
conformation of the Site 1 pocket in SHP2. NSC681129, ranked 21st in the positive hits from the screening,
was considered as the most promising lead compound (Figure S1). NSC681129-based structural
optimization was then performed to identify chemical structures that can potentially better stabilize the
intramolecular interaction between SH2 and PTP domains in SHP2 (Figure S1). NSC681129 was divided
into three parts - Fragment 1, Core, and Fragment 2. The Core structure and the two fragments were
5
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 6 of 49
1
2
3
4
5
6
7
8
9
replaced with chemical segments from a fragment database to fill up Site 1 and keep SHP2 in a closed
autoinhibited state. As a result, top 10 derivatives (LY1-LY10) with high docking scores were selected
(Figure S2). These derivatives along with the top 100 hits from the initial database screening were
subjected to PAINS (Pan Assay Interference Compounds) and aggregator examination26. Forty-seven
structures, including NSC681129, were identified as potential PAINS-group containing structures
(Supplementary PAINS Results). However, the 10 derivatives passed PAINS and aggregator tests and
therefore were synthesized (Figure S3 and S9). These molecular candidates were re-docked into Site 1 to
estimate their SHP2-binding affinities. The docking results showed that (E)-1-(1-(5-(3-(2,4-
dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1H-
benzo[d]imidazol-2(3H)-one (LY6, 1) had the best docking score (Figure S2). The Glide scoring was
conducted based on the sum of the Coulomb interaction energy, van der Waals energy, lipophilic and
hydrogen-bonding terms, and penalty which included factors that hindered binding. Van der Waals
interactions dominated all interactions between the ligands and the receptor. 1 was identified to have the
strongest van der Waals interaction energy among all candidates, and it formed a strong H-bond with
Glu250 and Thr218, indicating that 1 occupied the pocket better than other derivatives. The amino acids
involved at the binding site in SHP2 included Arg111, Phe113, His114, Gly115, His116, Leu117, Leu125,
Lys129, Leu136, Arg138, Thr218, Thr219, Arg220, Ile221, Ser228, Arg229, Glu232, Val243, Lys244,
Gln245, Gly246, Glu249, Glu250 and Thr253.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Identification of 1 as a novel SHP2 inhibitor. The ten candidate compounds were then subjected to SHP2
enzymatic assays with a tyrosine phosphorylated peptide as the substrate, which also served as an allosteric
activator. These compounds inhibited SHP2 phosphatase activity to various extents (Figure S4). LY1 and
LY7 were subsequently eliminated due to acute toxicity in cells. 1 was identified as the most active
6
ACS Paragon Plus Environment

Page 7 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
compound among the remaining compounds that inhibited SHP2 activity (Figure S4 and Figure 2A). As
PTPN11 (SHP2) activating mutations are mainly associated with JMML, which is characterized by
hypersensitity of myeloid progenitors to GM-CSF and IL-327, 28; it is critically important to determine the
inhibitory activity of 1 against the homologous SHP1 phosphatase because SHP2 and SHP1 play opposing
roles in these cytokine signaling pathways (due to the functional specificity determined by their SH2
domains). As shown in Figure 2B, 1 inhibited SHP2-catalyzed hydrolysis of the phospho-peptide substrate
with an IC50 value of 9.8 μM, whereas the IC50 of 1 for SHP1 was 72.7 μM. Although LY3 and LY5
showed good effects on SHP2, they inhibited the SHP1 phosphatase to a similar extent (i.e., no selectivity
between SHP2 and SHP1; data not shown). Therefore, LY3 and LY5 were eliminated.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Docking simulation analyses demonstrated that 1 created three hydrogen bonds with Arg111, Lys129, and
Arg229 (Figure S5A). Moreover, the dichloro-phenyl ring of 1 occupied the hydrophobic pocket made up
of Leu117, Leu125, Leu136, and Leu216. 1 possessed an L-shaped structure and fitted well in the pocket of
SHP2, connecting C-SH2 and PTP domains through hydrogen bonds and hydrophobic interactions. Binding
energy calculation showed that 1 occupied Site 1 with high binding energy (Figure S6A), similar to the
binding energy of the newly identified allosteric SHP-2 inhibitor SHP099 24 when docking into its binding
site (http://www.RCSB.org; PDB ID: 5EHR). While 1 docked into Site 1 with docking score of -7.3, it
could not dock into the SHP099 binding site due to limited space. Interestingly, 1 gained more binding
energy when docking into Site 1 than did SHP099 when docking into its binding site (Figure S6B).
Molecular dynamics (MD) simulation of the 1/SHP2 binding interaction. Many biological functions of
proteins and their profound dynamic mechanisms, such as switching between active and inactive states29,
cooperative effects30, allosteric transition31, and intercalations with drugs, can be revealed by studying their
7
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 8 of 49
1
2
3
4
5
6
internal motions. In order to understand the allosteric mechanism of a ligand with its receptor, both the
static structures and the dynamics information should be considered. Therefore, MD simulations were
7
8
9
performed to further define the 1/SHP2 interaction. The root mean square deviation (RMSD) as compared
with the initial conformation is a crucial criterion for evaluating the reliability and stability of drug/protein
systems. The RMSD of four complexes (SHP2-1, SHP1-1, SHP2 alone, and SHP1 alone) versus the
simulation times is illustrated in Figure S7A, in which the RMSD of the SHP2-1 interaction is lower than
those of the other systems, indicating that the movement of SHP2 might be circumscribed when binding
with 1, which would reduce the activity of SHP2 because activation of SHP2 requires protein
conformational changes from the closed autoinhibited conformation to the open conformation. In contrast,
the motion of SHP1 could hardly be suppressed by 1 during the simulation process.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In order to evaluate the motion of the key residues interacting with 1 at the binding site in SHP2 defined in
Figure S5A, the root mean square fluctuations (RMSF) for all residues of the SHP2 protein were
calculated. The most flexible region for SHP2 is made up of residues 111-206, corresponding to the C-SH2
domain. 1 was designed to concurrently bind to the C-SH2 domain and the PTP domain. The interaction
between 1 and the receptor SHP2 made the whole system stable, decreasing the flexibility of the C-SH2
domain in the meantime. The fluctuating magnitude of SHP2 decreased when binding to 1 (Figure S7B),
indicating that SHP2 is more stable when bond with 1. In contrast, 1 could hardly lower the movement of
key residues in SHP1 (Figure S7A and S7B), further supporting that 1 is selective for SHP2 over SHP1. 10
ns MD simulation of the 1/SHP2 binding (Figure S5B) predicts that 1 creates three hydrogen bonds with
Thr218, Arg220, and Arg229 of SHP2. The dichloro-phenyl ring of 1 is still in the hydrophobic region of
the pocket consisted of Leu117, Leu125, Leu136, and Leu216. The hydrogen bond between Arg111 and 1
is broken under MD simulation, while Arg111 forms a salt bridge with Glu250. By comparing the binding
8
ACS Paragon Plus Environment

Page 9 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
modes of 1 after and before MD simulations, it appears that 1 stays tightly in the binding pocket of SHP2,
indicating that the interaction between 1 and SHP2 is stable.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 also inhibits leukemia-associated mutant SHP2. The E76K mutation, localized in the N-SH2 domain,
is the most common and active PTPN11 mutation found in leukemias. This mutation causes a partially open
conformation in SHP2 due to the disruption of the intramolecular interaction. To further characterize the
acting mechanisms of 1, we purified GST fusion proteins of wild-type (WT) full-length SHP2 and the full-
length SHP2 E76K mutant, and compared sensitivities of these SHP2 proteins to 1. 1 inhibited the full
length SHP2 E76K mutant in a dose-dependent manner, with an IC50 value of 7.67 μM, which is slightly
lower than that for full length WT SHP2 (9.8 μM) (Figure 2C). The fact that the IC50 values of 1 for WT
SHP2 and SHP2 E76K were in a similar range suggests that 1 was able to “close” WT SHP2 and SHP2
E76K, regardless of the status of their basal conformations. Another possibility is that the phospho-peptide
substrate used in the phosphatase assay also functioned as an allosteric activator “opening up” protein
conformations of WT SHP2 and SHP2 E76K, regardless of the basal status, and similarly opened
conformations resulted in similar 1 concentrations required to achieve 50% inhibition of SHP2 enzymatic
activity.
We also tested the inhibitory effect of 1 on GST-SHP2 PTP domain without SH2 domains. It inhibited the
phosphatase activity of SHP2 PTP, although SHP2 PTP had a completely open conformation. This result
indicates that the binding of 1 with SHP2 PTP somehow interfered the peptide substrate-enzyme
interaction. However, the fact that the IC50 value (20.87 μM) of 1 for the SHP2 PTP domain was >2-fold
higher than that for full length WT SHP2 (Figure 2C) supports that 1 functions by stabilizing the inhibitory
closed conformation of full length SHP2. To further characterize the acting mechanisms of 1, we also tested
9
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 10 of 49
1
2
3
4
5
6
7
8
9
its effect on SHP2 catalytic activity using para-Nitrophenylphosphate (pNPP), a general small compound
substrate for all PTPs. pNPP is much smaller than the phospho-peptide substrate and can easily get access
to SHP2 catalytic core. Dephosphorylation of this small interrogate substrate does not require a substantial
conformational change in SHP2. Indeed, 1 did not affect the capability of SHP2 to dephosphorylate pNPP
(Figure 2D), regardless of what form of SHP2 protein was used as the enzyme, suggesting that 1 binding
does not interfere the access of this small substrate to SHP2 catalytic core.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Furthermore, we performed enzymatic kinetic studies (Lineweaver-Burk plot) in the absence or presence of
1. As shown in Figure 3A, Vmax decreased while Km increased when the 1/SHP2 binding increased with
increasing concentrations of 1, suggesting that 1 is a mixed type inhibitor against SHP2 (not a competitive
or non-competitive inhibitor). We also tested the inhibitory effect of 1 on SHP2 by extensively washing the
enzyme-inhibitor complex. The results indicated that the 1/SHP2 binding was stable (Figure S8A). In
addition, to exclude the possibility that the inhibition of SHP2 by 1 was a promiscuous effect, we tested the
activity of 1 in the presence of the detergent Triton X-100 and found that the 1-SHP2 complex was stable
and that the inhibitory function of 1 was not decreased by 0.001% Triton X-100 in the assay buffer (Figure
S8B). However, the inhibition of SHP2 by 1 was diminished by 0.01% Triton X-100, suggesting that the
1/SHP2 binding affinity is low. To further determine whether 1 directly bond to the SHP2 protein, we
performed the SHP2 fluorescence quenching assay, taking advantage of the seven tryptophans in the
protein. As demonstrated in Figure 3B, this drug exhibited strong quenching of SHP2 fluorescence in a
dose-dependent manner. Thermal shift assays also verified the binding of 1 and SHP2, as evidenced by
dose-dependent right shifts in melting temperature (Tm) (Figure 3C). Furthermore, quantitative MicroScale
Thermophoresis (MST) binding affinity assays demonstrated specific binding between 1 and His-tagged
SHP2 and that their interaction was not irreversible. The equilibrium dissociation constant (Kd) of the
10
ACS Paragon Plus Environment

Page 11 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
1/SHP2 complex was 69 ± 3 µM (Figure 3D). The Kd value of 1 derived from the MST assay was much
lower than its IC50 value from the phosphatase assay, likely because the buffer conditions, e.g., chemical
components and their concentrations, pH, etc. were significantly different in the two assays (different
solution conditions could effectively modify the strength of any intermolecular interactions holding a
particular ligand-protein complex together).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 inhibits SHP2-mediated cell signaling and cellular function. PTPN11 (SHP2) activating mutation-
associated JMML exhibits hypersensitivity to GM-CSF and IL-327, 28, and previous studies have
demonstrated that SHP2 promotes IL-3-stimulated cell proliferation by enhancing activation of Erk, Akt,
and Jak232, in sharp contrast to the SHP1 phosphatase, which negatively regulates these cytokines
signaling. It is critically important to test the effects of any potential SHP2 inhibitors in these cytokines
induced signaling and cellular responses. Ba/F3, an IL-3 dependent murine pro-B lymphoma cell line, was
utilized to determine the effects of 1 on SHP2-mediated cell signaling and cellular functions. This
compound significantly suppressed cell growth (Figure 4A), in agreement with the overall positive role of
SHP2 catalytic activity in cellular response to IL-3. To determine whether 1 functioned by inhibiting SHP2-
mediated cell signaling, we examined the effects of 1 on IL-3-induced signaling processes. Following IL-3
stimulation, activation of Erk, Akt, Jak2, and Stat5, determined by their phosphorylation levels, was
inhibited by 1 (Figure 4B and 4C), and this effect was clearly 1 dose-dependent, consistent with the
previous finding that SHP2 catalytic activity was required for optimal activation of IL-3-induced signaling
pathways32. These results suggest that 1 suppresses IL-3 signaling and cellular responses through a
mechanism involving inhibition of SHP2 catalytic activity.
1 has minimal off-target effects. To confirm that the cellular effects of 1 were mediated by acting on
11
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 12 of 49
1
2
3
4
5
6
7
8
9
SHP2, PTPN11 (SHP2) knockout cells were treated with 1. PTPN11 conditional knockout (PTPN11fl/fl/Ade-
Cre+) and WT control (PTPN11+/+/Ade-Cre+) mouse embryonic fibroblast (MEFs) were treated with 1 or
vehicle. Proliferation of WT cells was markedly decreased by this inhibitor, consistent with the positive
role that SHP2 plays in growth factor signaling1-3. In contrast, 1 did not show a significant effect on
PTPN11-depleted MEFs (Figure 5A). The observation that cells lacking SHP2 were insensitive to 1
suggests that SHP2 is the main target of this compound.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Tumor cells carrying SHP2 activating mutations are more sensitive to 1 than control cells with WT
SHP2. We next assessed the effect of 1 on mutant cells with a tumor-associated PTPN11 activating
mutation (PTPN11E76K). Treatment of both WT and PTPN11E76K/+ MEFs with 1 significantly decreased cell
growth (Figure 5B). Interestingly, PTPN11E76K/+ mutant cells were much more sensitive than WT cells to
SHP2 inhibition although the IC50 value of 1 for the SHP2 E76K mutant was only slightly lower than that
for WT SHP2. Additionally, human lung cancer cells H661 carrying the activating mutation (N58S) in
PTPN11 and human lung cancer cells H596 with WT PTPN11 were treated with 1. This compound
inhibited proliferation of both two cell lines in a dose-dependent manner. Importantly, H661 cells were
more sensitive to 1 than H596 cells (Figure 6A). Moreover, 1-treated H661 cells showed pronounced G2/M
arrest (Figure 6B), consistent with the positive role of SHP2 in cell cycle progression33.
We next determined whether 1 could suppress colony formation and proliferation of mouse and human
leukemic cells with PTPN11 activating mutations. Myeloid progenitors from PTPN11E76K/+ mice showed
greatly increased responses to GM-CSF as compared to WT counterparts. These SHP2 E76K-expressing
progenitors were much more sensitive than control cells to 1 inhibition of colony-forming capabilities over
a range of concentrations (Figure 7A). Consistent with this data, colony formation of myeloid blasts from
12
ACS Paragon Plus Environment

Page 13 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
JMML patients with the PTPN11E76K/+ mutation was exquisitely sensitive to 1 (Figure 7B). Overall, these
results suggest that 1 is able to overcome the dominant effects of SHP2 activating mutations in primary
mouse and patient cells, and that SHP2 is a useful therapeutic target for PTPN11 mutation-associated
hematological malignancies.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
DISCUSSION AND CONCLUSIONS
In this study, by using CADD in silico database screening in combination with experimental assays, we
have identified a new SHP2 inhibitor. SHP2, encoded by PTPN11, is an important signaling component
downstream of growth factor/cytokine receptors and cell adhesion molecules. Activating mutations of
PTPN11 that cause enhanced catalytic activity are associated with human diseases, such as Noonan
syndrome and childhood leukemias7, 10-12. Importantly, these mutations play a causative role in the
pathogenesis of these diseases14-16. Therefore, identification of highly selective SHP2 inhibitors is greatly
needed and would facilitate the development of therapeutic drugs for these diseases. However, it has been
challenging to develop SHP2 selective inhibitors that directly target the active site due to a high homology
in these sites among tyrosine phosphatases. To circumvent this problem, a few allosteric inhibitors of SHP2
that inhibit the conformational change required for activation of this enzyme have recently been
successfully developed23-25. Our structure-based approach in this study was also targeting the activation-
associated conformational change, but a different surface pocket formed between C-SH2 and PTP
domains. We have identified a novel SHP2 inhibitor (1) through CADD database screening, structural
optimization, and cell-based assays.
Structure-activity relationship analyses of optimized derivatives suggest that three parts of 1 function
cooperatively in keeping the “closed” auto-inhibited conformation of SHP2. (1) The Core part of 1 is
13
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 14 of 49
1
2
3
4
5
6
7
8
9
responsible for an interaction with the PTP domain. The hydroxyl group of the Core part (beta-
methyloxygenly phenol group) forms firm connections with key residues of the PTP domain via H-bond
interactions. The methoxyl group and benzene ring interact with Lys129 and Tyr515 via intermolecular
forces. (2) R1 of Fragment 1 acts as a linker of the SH2 domain to stabilize its position by hydrophobic
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
effects and VDW interactions. (3) R2 and R3 of Fragment 2 provide benzene ring effects and possibly other
molecular interactions with the SH2 domain. In addition, PTP and SH2 domains are firmly connected via
two Cl atoms of Fragment 2. 1 inhibits SHP2 activity toward a pY-peptide substrate, but not the small
compound substrate pNPP (Figure 2D). This is because pY-peptide substrates rely more on SHP2 protein
conformational changes than pNPP in order to get access to the catalytic core to be dephosphorylated. It is
likely that 1 functions by inhibiting the activation-associated allosteric change of SHP2, as designed, not
targeting the active site. Computational modeling shows that the structure of 1 complements very well the
binding pocket in SHP2 in docking simulation. In addition, MD simulation demonstrates that movement of
the SHP2 protein is suppressed upon binding with 1, further supporting that the auto-inhibitory protein
conformation of SHP2 is stabilized by 1.
PTPN11 (SHP2) activating mutations are associated with JMML, which display a characteristic
hypersensitive growth pattern in response to GM-CSF and IL-327, 28. 1 inhibited IL-3-stimulated cell
proliferation and suppressed IL-3-induced Ras-Erk, PI3K-Akt, and Jak2-Stat5 pathways. Given the positive
roles that the SHP2 phosphatase plays in these signaling pathways, the function of 1 in this context is likely
mediated by inhibition of the catalytic activity of SHP2. Interestingly, mouse and human leukemia cells
carrying the activating mutation SHP2 E76K were much more sensitive than control cells with WT SHP2
to the inhibition by 1 (Figure 7), although the SHP2 E76K protein was only slightly more sensitive to 1
than WT SHP2 (Figure 2C). Part of the reason for this might be the addiction of leukemic cells to this
14
ACS Paragon Plus Environment

Page 15 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
disease causing oncoprotein. The differential sensitivity of PTPN11 activated leukemia cells and normal
control cells to SHP2 inhibition provides proof of concept that SHP2 is a “druggable” target for the
treatment of PTPN11-associated malignancies.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1 appears to function as an allosteric inhibitor of SHP2, despite a low SHP2-binding affinity. This inhibitor
and the allosteric SHP-2 inhibitor SHP099 recently identified 24 have different binding sites and activities. 1
was designed to bind to the surface pocket of SHP2 formed between C-SH2 and PTP domains. This drug
docking site (Site 1) is different from the binding site of SHP099 24, which concomitantly binds to N-SH2,
C-SH2 and PTP domains (http://www.RCSB.org; PDB ID: 5EHR). Given that the structures and the SHP2-
binding sites of these two inhibitors are completely different, they have distinct biochemical activities in
inhibiting the function of WT SHP2 and SHP2 variants. This is especially the case when different phospho-
peptides or interrogate compounds were used as the substrate in phosphatase assays. More
biochemical/biological studies with tumor-associated mutant SHP2 and SHP2-mutated tumor cells will be
necessary to further compare the functions of these two inhibitors. It is important to point out that while 1 is
a drug-like small molecule that is bioavailable in cells, 1/SHP2 binding affinity is low. Further structure-
activity relationship analysis for this compound is needed to establish independent intellectual property
positions that will allow pharmacological validation of its effect on SHP2 inhibition for the development of
analogues for further preclinical and clinical studies. In addition, cocrystallization of 1 and SHP2 is
required to reveal the structural bases of their binding interaction, which will be essential for structural
optimization of 1. The structural bases of the 1/SHP2 binding can also address the mechanisms of action of
this inhibitor and other related questions regarding the biochemical activities of ths inhibitor.
EXPERIMENTAL SECTION
15
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 16 of 49
1
2
3
4
Reagents and Chemicals. The CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was
5
6
7
8
purchased from Promega (Madison, WI, USA). Antibodies specific for p-Erk (E-4), Erk (C-16), Jak2 (C-
20), and SHP2 (C-18) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
Antibodies against p-Akt (S473), Akt, and p-Stat5 (Y694) were obtained from Cell Signaling Technology
(Beverly, MA, USA). Stat5 antibody was purchased from BD Biosciences (San Jose, CA, USA).
Antibodies specific for p-Jak2 (Y1007/1008) and phosphor-tyrosine (pY) were purchased from Millipore
Corporation (Temecula, CA, USA). Horseradish peroxidase conjugated goat-anti-rabbit and anti-mouse
IgG were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). Dimethyl
sulfoxide and other chemicals used for buffer solutions were provided by Fisher Scientific (Pittsburgh, PA,
USA). LY series compounds, including 1, were obtained from Tianjin Institute of Pharmaceutical Research.
(Tianjin, China), and dissolved in DMSO to prepare a stock solution (20 mM) for subsequent experiments.
The purity of all test compounds was ≥ 98% by HPLC.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Compound Synthesis and Characterization. 1 was synthesized using 1-(2,4-dihydroxyphenyl) ethan-1-
one and diethyl sulfate as starting materials with 4-step reactions (Figure S3). Synthesis of other derivatives
is described in Figure S9.
1-(4-ethoxy-2-hydroxyphenyl) ethan-1-one. A mixture of 1-(2,4-dihydroxyphenyl) ethan-1-one (19.8g, 130
mmol) and diethyl sulfate (40.5g, 520 mmol) was stirred in 300 mL acetone at room temperature for 24
hours. The solution was heated to reflux for 1 hour and then filtered. Desolventized mixture was washed by
50 mL water 3 times and extracted by 100 mL Ethyl Acetoacetate 3 times. A crude product [(Building block
(2)] was obtained. The product was used in the next step without any further purification.
1-(5-(chloromethyl)-4-ethoxy-2-hydroxyphenyl) ethan-1-one. Building block (2) (15.0g, 83 mmol) was
16
ACS Paragon Plus Environment

Page 17 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
dissolved in chloromethyl methyl ether (14.0g, 122 mmol). The solution was diluted in 100 mL acetic acid
and stirred at ambient temperature for 24 hours. After removing the solvent under reduced pressure, the
product [(Building block (3)] (7.7g, 33.6 mmol) was obtained with yield of 27.5%.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1-(1-(5-acetyl-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1,3-dihydro-2H-benzo[d]imidazol-
2-one. K2CO3 (1.74g, 12.6 mmol) and 1-(1,2,5,6- tetrahydropyridin-3-yl)-1H-benzo[d]imidazol-2(3H)-one
(11g, 50.4 mmol) were added into the solution of Building block (3) (7.7g, 33.6 mmol) in 30 mL Ethyl
Acetoacetate at room temperature and stirred for 24 hours. The solvent was removed under reduced
pressure, and then washed by brine and 1 M hydrochloric acid 3 times, respectively. The solution was
extracted by Ethyl Acetoacetate after adjusting pH to 8-9 by 1 M K2CO3. After the volatile solvent of the
reaction was evaporated, 15.3g yellow pale oily raw product [(Building block (4)] was obtained.
(E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1H-
benzo[d]imidazol-2(3H)-one. Building block (4) (1.12g, 2.5 mmol), 2,4-dichlorobenzaldehyde (0.88g, 5
mmol), and 0.7g KOH (0.7g, 12 mmol) were mixed and stirred in 9 mL ethanol and 2 mL water at room
temperature for 24 hours. The product was recrystallized in 15 mL ethanol after discarding the volatile
solvent. 0.3g compound (22.4%) was obtained as the final product (LY6, 1). The purity and the structure of
this final product were determined by High-performance liquid chromatography (HPLC) and Nuclear
magnetic resonance (NMR), respectively (Supplementary HPLC and NMR results).
Virtual Screening and Core-Hopping Procedure in Silico. The database of small structures from NCI,
USA was screened by the Glide docking package of the Schrodinger suite 201034 based on the 3D structure
of residues in the designated binding pocket in SHP2. Protein and small compound structures were geared
up by Protein Preparation Wizard and LigPrep modules embedded in Schrodinger suite 2010
17
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 18 of 49
1
2
3
4
(www.schrodinger.com)35, respectively. All investigated structures in the NCI database were docked into
5
6
7
8
the defined pocket using the rigid docking model with the stand-precision scoring function34, 36 to estimate
the binding affinities. In order to enhance binding affinity, the program Core-Hopping36 in Schrodinger
suite 2010 was utilized in this study, which had dual functions (including fragment-based replacing and
molecular docking). OPLS2005 force field37, 38 was recruited in all assays performed in silico.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Molecular Dynamics (MD) Simulation. To examine whether the inhibitor remains bound in the presence
of explicit solvent from a dynamic point of view, the MD simulation was performed with GROMACS 96-
53a6 force fields39 with the periodic boundary conditions by using the GROMACS 4.5 package for Linux.
The topology files and charges for the ligand atoms were generated by the Dundee PRODRG2.5 Server40.
After minimization of the potential energy of the whole system, 10 ns MD simulations were carried out
with a time interval of 2 fs; corresponding coordinates were stored every 10 fs. The PME algorithm was
used to calculate the electrostatic interactions. All simulations were run under the periodic boundary
condition with NVT ensemble by using the V-rescale coupling algorithm to keep the temperature at 310 K
and pressure at 1atm. All bonds were constrained by using the LINCS algorithm. The GROMACS 4.5
package was utilized to analyze the results. The initial complex structures of 1-SHP1 and 1-SHP2 for MD
simulation were from docking calculations (Supplementary PDB File 1 and 2).
Protein-Ligand Binding Energy Calculation. The binding energy was calculated as follows. The
coulomb interaction energies between protein and ligand were computed by equation (1) where qi and qj
were the formal charge associated with atomic centers i and j, which were the residues in the C-SH2 and
PTP domain, respectively. Rij was the distance between them. F = 138.935 and εr was the dielectric
constant.
18
ACS Paragon Plus Environment

Page 19 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
푞 푞
푖
푗
∑
Vc = i,j [푓 휀 푅
]
(1)
(2)
푟
푖푗
The van der Waals interaction energies between protein and ligand equals:
(12)
푖푗
(6)
퐶
퐶
푖푗
∑
VVDW
=
[
−
]
푅
푖푗
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
i,j
6
12
푅
푖푗
(12)
푖푗
(12) (12)
√
퐶
= Cii
C
(3)
(4)
jj
(6)
푖푗
(6) (6)
√
= Cii C
jj
퐶
As the parameters Cij(6) and Cij(12) depend on pairs of atom types, they were taken from a matrix of
Lennard-Jones parameters. Rij was the distance between them.
In Vitro Phosphatase Activity Assay. Purified SHP2 and SHP1 phosphatases purchased from Enzo Life
Sciences (Farmingdale, NY, USA) were used as enzymes and a phospho-peptide (H-Glu-Phe-pTyr-Ala-
Glu-Val-Gly-Arg-Ser-Pro-Pro-Asp-Pro-Ala-Lys) (BML-P157, Enzo Life Sciences Inc., NY, USA) was used
as the substrate, which also functions as an activator of SHP2 by binding to the N-SH2 domain. The assay
determines free phosphate generated by dephosphorylation of the substrate by using the Malachite Green
reagent (Sigma, St. Louis, MO, USA). In brief, 0.1 μg of SHP2 or SHP1 was incubated in 40 μL of the
assay buffer (25 mM Tris-HCl, pH 7.4, 50 mM NaCl, 5 mM DTT, and 2.5 mM EDTA) with test
compounds at various concentrations at room temperature for 30 min. The substrate was then added to a
final concentration of 50 µM. The mixture was incubated at 30 °C for 30 min. Finally, 50 μL of Malachite
Green solution was added and OD620 was measured after 10 min. Under these conditions, the absorbance
readings of the phosphatase assays with SHP2 E76K or SHP2 PTP as the enzyme were still within the
linear calibration range. For the phosphatase assay with pNPP as the substrate, 0.1 μg of SHP2 or its
mutants was incubated in 60 µL of the assay buffer as above with 1 at various concentrations at 37 °C for
19
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 20 of 49
1
2
3
4
15 min, followed by addition of 90 µL of pNPP to the final concentration of 0.9 mg/ml. The mixture was
5
6
incubated at 37 °C for 15 min and OD405 was then measured.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Fluorescence Titrations. Purified full length WT SHP2 GST-fusion protein was diluted into 20 mM Tris-
HCl, pH 7.5. Fluorescence spectra were recorded with a Luminescence Spectrometer LS50 (Perkin-Elmer,
Boston, MA, USA). Titrations were performed by increasing the concentration of the compound while
maintaining the SHP2 protein concentration at 3.0 μM. Contributions from background fluorescence of the
inhibitor were accounted for by subtracting the fluorescence of the inhibitor alone from the protein-
inhibitor solution. The excitation wavelength was 295 nm and fluorescence was monitored from 360 to 500
nm. All reported fluorescence intensities were relative values and were not corrected for wavelength
variations in detector response.
Thermal Shift Assay. Thermal shift assays were performed as previously described 41, 42. In brief, in a 20
µl final reaction system, purified His-tagged SHP2 protein (1 µg) in the buffer (50 mM Tris-HCl, pH 8.0,
500 mM NaCl, and 50 mM imidazole) was mixed with 10 µl 5x Sypro Orange Protein Gel Stain (Life
Technologies) (diluted in 100 mM HEPES, pH 7.5). 0.2 µl compound 1 dissolved in DMSO was added to
final concentrations of 5, 10, and 60 µM. 1% (V/V) DMSO was used as the control. Samples were heated
in a QuantStudio 3 Real-Time PCR System (ThermoFisher Scientific) from 22°C to 95°C in steps of 1°C
every 50 sec. Melting curves were analyzed with Protein Thermal Shift Software Version 1.3
(ThermoFisher Scientific) to determine melting temperature (Tm).
MicroScale Thermophoresis (MST) Assay. Purified His-tagged SHP2 protein (200 nM) in 100 µL buffer
(50 mM Tris-HCl, pH 8.0, 10 mM NaCl, and 0.005% Tween 20) was labeled with red-tris-NTA dye using a
Monolith NTTM His-tag labeling kit (NanoTemper Technologies) following the protocol provided by the
20
ACS Paragon Plus Environment

Page 21 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
manufacturer. 1 (600 μM) was diluted with PBST (PBS buffer containing 0.005% Tween 20) in 15 2-fold
serial dilutions. 10 μL labeled protein was mixed with 10 µL diluted 1 at various concentrations, and the
mixtures were loaded to standard capillaries. Binding assays were run with a red filter on a Monolith
NT.115 (NanoTemper Technologies). Automated MST measurement was performed with an MST power of
50%. The resulting dose-response curve was fitted to a one-site binding model to extract a Kd value.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Western Blot Analysis. Ba/F3 cells were starved overnight in serum-free and cytokine-free RPMI1640.
Cells were then treated with 1 for 4 hours before stimulation with IL-3 (2 ng/mL). Stimulated cells were
harvested and lysed on ice with RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF and protease
inhibitor cocktail (Roche, Indianapolis, IN, USA). Equivalent amounts of protein (50 μg) were resolved on
10% SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Bedford, MA, USA). Membranes
were blocked with 2% BSA in TBS (20 mM Tris-HCl, pH 7.4 and 150 mM NaCl) for 1 hour at room
temperature and probed with primary antibodies overnight at 4°C. Blots were washed with TBST and
exposed to HRP conjugated goat-anti-mouse or goat-anti-rabbit secondary antibodies for 1 hour at room
temperature. Immunoreactive bands were detected by using ECL Plus Reagents (GE Healthcare,
Piscataway, NJ, USA).
Colony-Forming Unit Assay. Mouse bone marrow cells (2×104 cells/mL) or patient splenocytes or blood
cells (5×104 cells/mL) were assayed for colony forming units (CFUs) in 0.9% methylcellulose IMDM
containing 30% FBS, glutamine (10-4 M), β-mercaptoethanol (3.3×10-5 M), GM-CSF (1.0 ng/mL), and
varying concentrations of 1 or the equivalent amount of DMSO. After 7 days (mouse bone marrow cells) or
14 days (patient cells) of culture at 37°C in a humidified 5% CO2 incubator, myeloid colonies (CFU-GM
21
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 22 of 49
1
2
3
4
and CFU-M) were counted under an inverted microscope.
5
6
7
8
9
Statistical Analysis. Data are presented as mean ± SD. Statistical significance was determined using
unpaired two-tailed Student’s t test. p<0.05 was considered statistically significant.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ACKNOWLEDGMENTS
This work was supported by the National Institutes of Health grant HD087760 and a Hyundai Hope on
Wheels Scholar grant (to C.K.Q.).
AUTHORSHIP CONTRIBUTIONS
X.W., G.X., X.L., W.R.X., W.L., Q.L., and K.A.K. conducted the research and summarized the data.
M.L.L., J.L., and S.G.S. provided critical reagents and advice on the work. C.K.Q. designed the
experiments and provided technical training to the first three authors. X.W., G.X., X.L., W.R.X., and
C.K.Q. wrote the manuscript and input from all authors.
CONFLICT-OF-INTEREST DISCLOSURE
The authors declare no competing financial interests.
ANCILLARY INFORMATION
Supporting Information: Supplementary Figure S1 to Figure S9; Top hits from the initial virtual database
screening; PAINS results of the top 100 hits from the initial database screening and the ten derivatives of
NSC681129; The complex structure of 1 and SHP1 in the PDB format (PDB file 1); The complex structure
of 1 and SHP2 in the PDB format (PDB file 2); Molecular formula strings of 1 (CSV file); Proton NMR
data of 1; Proton NMR spectra data of 1; NMR results of other derivatives synthesized; HPLC data of all
22
ACS Paragon Plus Environment

Page 23 of 49
Journal of Medicinal Chemistry
1
2
3
derivatives synthesized.
4
5
6
7
8
9
Correspondence: Cheng-Kui Qu at cheng-kui.qu@emory.edu
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Abbreviations used: SHP-2: Src homology 2 domain-containing phosphatase 2; PTP: Protein tyrosine
phosphatase; SH2: Src homology 2; pY: Phosphotyrosine; pNPP: para-Nitrophenylphosphate; NS: Noonan
Syndrome; JMML: Juvenile myelomonocytic leukemia; WT: Wildtype; CFU: Colony forming unit;
CADD: Computer-aided drug design. MST: MicroScale Thermophoresis. NMR: Nuclear magnetic
resonance; HPLC: High-performance liquid chromatography.
REFERENCES
1.
cell signaling. Trends in biochemical sciences 2003, 28, 284-93.
2. Tonks, N. K. Protein tyrosine phosphatases: from genes, to function, to disease. Nature reviews.
Molecular cell biology 2006, 7, 833-46.
3. Xu, D.; Qu, C. K. Protein tyrosine phosphatases in the JAK/STAT pathway. Frontiers in bioscience
: a journal and virtual library 2008, 13, 4925-32.
4. Hof, P.; Pluskey, S.; Dhe-Paganon, S.; Eck, M. J.; Shoelson, S. E. Crystal structure of the tyrosine
phosphatase SHP-2. Cell 1998, 92, 441-50.
5. Eck, M. J.; Pluskey, S.; Trub, T.; Harrison, S. C.; Shoelson, S. E. Spatial constraints on the
Neel, B. G.; Gu, H.; Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in
recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379,
277-80.
6.
Barford, D.; Neel, B. G. Revealing mechanisms for SH2 domain mediated regulation of the protein
23
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 24 of 49
1
2
3
4
5
6
tyrosine phosphatase SHP-2. Structure 1998, 6, 249-54.
7. Loh, M. L.; Vattikuti, S.; Schubbert, S.; Reynolds, M. G.; Carlson, E.; Lieuw, K. H.; Cheng, J. W.;
7
8
9
Lee, C. M.; Stokoe, D.; Bonifas, J. M.; Curtiss, N. P.; Gotlib, J.; Meshinchi, S.; Le Beau, M. M.; Emanuel, P.
D.; Shannon, K. M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004,
103, 2325-31.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8.
Tartaglia, M.; Martinelli, S.; Cazzaniga, G.; Cordeddu, V.; Iavarone, I.; Spinelli, M.; Palmi, C.;
Carta, C.; Pession, A.; Arico, M.; Masera, G.; Basso, G.; Sorcini, M.; Gelb, B. D.; Biondi, A. Genetic
evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to
leukemogenesis in childhood acute leukemia. Blood 2004, 104, 307-13.
9.
Loh, M. L.; Reynolds, M. G.; Vattikuti, S.; Gerbing, R. B.; Alonzo, T. A.; Carlson, E.; Cheng, J. W.;
Lee, C. M.; Lange, B. J.; Meshinchi, S. PTPN11 mutations in pediatric patients with acute myeloid leukemia:
results from the Children's Cancer Group. Leukemia 2004, 18, 1831-4.
10.
Tartaglia, M.; Niemeyer, C. M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.;
Licht, J. D.; Gelb, B. D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia,
myelodysplastic syndromes and acute myeloid leukemia. Nature genetics 2003, 34, 148-50.
11.
Tartaglia, M.; Mehler, E. L.; Goldberg, R.; Zampino, G.; Brunner, H. G.; Kremer, H.; van der Burgt,
I.; Crosby, A. H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M. A.; Kucherlapati, R. S.; Gelb, B. D. Mutations
in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature genetics
2001, 29, 465-8.
12.
Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.;
Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J.; Girard, L.; Minna, J. D.; Loh, M. L.;
Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Sellers, W. R.; Neel, B. G. Activating
mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute
24
ACS Paragon Plus Environment

Page 25 of 49
Journal of Medicinal Chemistry
1
2
3
myelogenous leukemia. Cancer research 2004, 64, 8816-20.
4
5
6
13.
Keilhack, H.; David, F. S.; McGregor, M.; Cantley, L. C.; Neel, B. G. Diverse biochemical
7
8
9
properties of Shp2 mutants. Implications for disease phenotypes. The Journal of biological chemistry 2005,
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
280, 30984-93.
14.
Chan, G.; Kalaitzidis, D.; Usenko, T.; Kutok, J. L.; Yang, W.; Mohi, M. G.; Neel, B. G.
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple
stages of hematopoiesis. Blood 2009, 113, 4414-24.
15.
Xu, D.; Liu, X.; Yu, W. M.; Meyerson, H. J.; Guo, C.; Gerson, S. L.; Qu, C. K. Non-lineage/stage-
restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant
transformation of hematopoietic cells. The Journal of experimental medicine 2011, 208, 1977-88.
16.
Araki, T.; Mohi, M. G.; Ismat, F. A.; Bronson, R. T.; Williams, I. R.; Kutok, J. L.; Yang, W.; Pao, L.
I.; Gilliland, D. G.; Epstein, J. A.; Neel, B. G. Mouse model of Noonan syndrome reveals cell type- and gene
dosage-dependent effects of Ptpn11 mutation. Nature medicine 2004, 10, 849-57.
17.
Chen, L.; Sung, S. S.; Yip, M. L.; Lawrence, H. R.; Ren, Y.; Guida, W. C.; Sebti, S. M.; Lawrence,
N. J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular pharmacology
2006, 70, 562-70.
18.
Geronikaki, A.; Eleftheriou, P.; Vicini, P.; Alam, I.; Dixit, A.; Saxena, A. K. 2-
Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.
Journal of medicinal chemistry 2008, 51, 5221-8.
19.
Hellmuth, K.; Grosskopf, S.; Lum, C. T.; Wurtele, M.; Roder, N.; von Kries, J. P.; Rosario, M.;
Rademann, J.; Birchmeier, W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by
high-throughput docking. Proceedings of the National Academy of Sciences of the United States of America
2008, 105, 7275-80.
25
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 26 of 49
1
2
3
4
20.
Lawrence, H. R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S. S.; Szymanski, A. M.; Yip, M. L.; Guida,
5
6
W. C.; Sebti, S. M.; Wu, J.; Lawrence, N. J. Inhibitors of Src homology-2 domain containing protein tyrosine
7
8
9
phosphatase-2 (Shp2) based on oxindole scaffolds. Journal of medicinal chemistry 2008, 51, 4948-56.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21.
Zhang, X.; He, Y.; Liu, S.; Yu, Z.; Jiang, Z. X.; Yang, Z.; Dong, Y.; Nabinger, S. C.; Wu, L.;
Gunawan, A. M.; Wang, L.; Chan, R. J.; Zhang, Z. Y. Salicylic acid based small molecule inhibitor for the
oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). Journal of medicinal
chemistry 2010, 53, 2482-93.
22.
Liu, W.; Yu, B.; Xu, G.; Xu, W. R.; Loh, M. L.; Tang, L. D.; Qu, C. K. Identification of
cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). Journal of
medicinal chemistry 2013, 56, 7212-21.
23.
the oncogenic protein tyrosine phosphatase Shp2. Biochemistry 2015, 54, 497-504.
24. Chen, Y. N.; LaMarche, M. J.; Chan, H. M.; Fekkes, P.; Garcia-Fortanet, J.; Acker, M. G.;
Chio, C. M.; Lim, C. S.; Bishop, A. C. Targeting a cryptic allosteric site for selective inhibition of
Antonakos, B.; Chen, C. H.; Chen, Z.; Cooke, V. G.; Dobson, J. R.; Deng, Z.; Fei, F.; Firestone, B.; Fodor,
M.; Fridrich, C.; Gao, H.; Grunenfelder, D.; Hao, H. X.; Jacob, J.; Ho, S.; Hsiao, K.; Kang, Z. B.; Karki, R.;
Kato, M.; Larrow, J.; La Bonte, L. R.; Lenoir, F.; Liu, G.; Liu, S.; Majumdar, D.; Meyer, M. J.; Palermo, M.;
Perez, L.; Pu, M.; Price, E.; Quinn, C.; Shakya, S.; Shultz, M. D.; Slisz, J.; Venkatesan, K.; Wang, P.;
Warmuth, M.; Williams, S.; Yang, G.; Yuan, J.; Zhang, J. H.; Zhu, P.; Ramsey, T.; Keen, N. J.; Sellers, W. R.;
Stams, T.; Fortin, P. D. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine
kinases. Nature 2016, 535, 148-52.
25.
Garcia Fortanet, J.; Chen, C. H.; Chen, Y. N.; Chen, Z.; Deng, Z.; Firestone, B.; Fekkes, P.; Fodor,
M.; Fortin, P. D.; Fridrich, C.; Grunenfelder, D.; Ho, S.; Kang, Z. B.; Karki, R.; Kato, M.; Keen, N.;
LaBonte, L. R.; Larrow, J.; Lenoir, F.; Liu, G.; Liu, S.; Lombardo, F.; Majumdar, D.; Meyer, M. J.; Palermo,
26
ACS Paragon Plus Environment

Page 27 of 49
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
M.; Perez, L.; Pu, M.; Ramsey, T.; Sellers, W. R.; Shultz, M. D.; Stams, T.; Towler, C.; Wang, P.; Williams, S.
L.; Zhang, J. H.; LaMarche, M. J. Allosteric Inhibition of SHP2: Identification of a potent, selective, and
orally efficacious phosphatase inhibitor. Journal of medicinal chemistry 2016, 59, 7773-82.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26.
Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference
compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of medicinal
chemistry 2010, 53, 2719-40.
27.
Emanuel, P. D.; Bates, L. J.; Castleberry, R. P.; Gualtieri, R. J.; Zuckerman, K. S. Selective
hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia
hematopoietic progenitors. Blood 1991, 77, 925-9.
28.
Shannon, K. M. Nf1 and Gmcsf interact in myeloid leukemogenesis. Molecular cell 2000, 5, 189-95.
29. Sun, S. X.; Li, X. B.; Liu, W. B.; Ma, Y.; Wang, R. L.; Cheng, X. C.; Wang, S. Q.; Liu, W. Design,
Birnbaum, R. A.; O'Marcaigh, A.; Wardak, Z.; Zhang, Y. Y.; Dranoff, G.; Jacks, T.; Clapp, D. W.;
synthesis, biological activity and molecular dynamics studies of specific protein tyrosine phosphatase 1B
inhibitors over SHP-2. International journal of molecular sciences 2013, 14, 12661-74.
30.
Chou, K. C. Low-frequency resonance and cooperativity of hemoglobin. Trends in biochemical
sciences 1989, 14, 212-3.
31.
Chou, K. C. The biological functions of low-frequency vibrations (phonons). 4. Resonance effects
and allosteric transition. Biophysical chemistry 1984, 20, 61-71.
32.
SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene 2003, 22, 5995-6004.
33. Bennett, A. M.; Hausdorff, S. F.; O'Reilly, A. M.; Freeman, R. M.; Neel, B. G. Multiple
Yu, W. M.; Hawley, T. S.; Hawley, R. G.; Qu, C. K. Catalytic-dependent and -independent roles of
requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Molecular and
cellular biology 1996, 16, 1189-202.
27
ACS Paragon Plus Environment

Journal of Medicinal Chemistry
Page 28 of 49
1
2
3
4
34.
Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.;
5
6
Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of
7
8
9
hydrophobic enclosure for protein-ligand complexes. Journal of medicinal chemistry 2006, 49, 6177-96.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35.
Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand
preparation: parameters, protocols, and influence on virtual screening enrichments. Journal of computer-
aided molecular design 2013, 27, 221-34.
36.
hemagglutinin against H1N1 influenza virus by core hopping method. PloS one 2011, 6, e28111.
37. Shivakumar, D.; Harder, E.; Damm, W.; Friesner, R. A.; Sherman, W. Improving the prediction of
Li, X. B.; Wang, S. Q.; Xu, W. R.; Wang, R. L.; Chou, K. C. Novel inhibitor design for
absolute solvation free energies using the next generation OPLS force field. Journal of chemical theory and
computation 2012, 8, 2553-8.
38.
Shivakumar, D.; Williams, J.; Wu, Y.; Damm, W.; Shelley, J.; Sherman, W. Prediction of absolute
solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. Journal
of chemical theory and computation 2010, 6, 1509-19.
39.
GROMOS force field. European biophysics journal : EBJ 2005, 34, 273-84.
40. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of
protein-ligand complexes. Acta crystallographica. Section D, Biological crystallography 2004, 60, 1355-63.
41. Pantoliano, M. W.; Petrella, E. C.; Kwasnoski, J. D.; Lobanov, V. S.; Myslik, J.; Graf, E.; Carver, T.;
Oostenbrink, C.; Soares, T. A.; van der Vegt, N. F.; van Gunsteren, W. F. Validation of the 53A6
Asel, E.; Springer, B. A.; Lane, P.; Salemme, F. R. High-density miniaturized thermal shift assays as a
general strategy for drug discovery. Journal of biomolecular screening 2001, 6, 429-40.
42.
Lo, M. C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. Evaluation of
fluorescence-based thermal shift assays for hit identification in drug discovery. Analytical biochemistry
28
ACS Paragon Plus Environment

Page 29 of 49
Journal of Medicinal Chemistry
1
2
3
2004, 332, 153-9.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
29
ACS Paragon Plus Environment